Research programme: psoriasis therapeutic - BioLineRx

Drug Profile

Research programme: psoriasis therapeutic - BioLineRx

Alternative Names: BL-7020

Latest Information Update: 26 Mar 2013

Price : $50

At a glance

  • Originator BioRap; The Tel Aviv Sourasky Medical Center
  • Developer BioLineRx
  • Class Recombinant proteins
  • Mechanism of Action Keratinocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 01 Mar 2013 Discontinued - Preclinical for Psoriasis in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top